NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Karyopharm Therapeutics Inc. (KPTI) Stock Analysis

Karyopharm Therapeutics Inc. (KPTI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KPTI

$0.42

+$0.07 (+18.35%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KPTI with… →

KPTI Key Statistics

As of Oct 21, 2026
Trading
Open
$0.36
Previous Close
$0.36
Day's Range
0.36–0.44
52-Week Range
0.31–10.99
Volume
1.55M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.04
Valuation
Market Cap
$9.63M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.07
EPS (ttm)Profit attributable to each share over the last twelve months.
−14.33
Financials (FY)
Revenue (FY)
$146.07M+0.57%
Net Income (FY)
−$196.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
−153.28%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
22.68M
1-Year Return
−93.40%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.81M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KPTI closed at $0.42, −93.40% over 1 year.

Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $9.63M.

In fiscal 2025, KPTI reported revenue of $146.07M.

KPTI Stock Return by Calendar Year

Karyopharm Therapeutics Inc. (KPTI) 10-year return: what $10,000 became

1 year
$10,000 $660
−93.40%
5 years
$10,000 $53
−99.47%
10 years
$10,000 $33
−99.67%

If you had invested $10,000 in Karyopharm Therapeutics Inc. (KPTI) 10 years ago, at the close on October 21, 2016, it would have been worth $33 at the close on October 21, 2026: −99.67% in total, −43.54% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−94.23%
2025−27.42%
2024−21.85%
2023−74.56%
2022−47.12%
2021−58.46%
2020−19.25%
2019+104.59%
2018−2.40%
2017+2.13%
2016 (partial year)+38.44%

As of October 21, 2026.

KPTI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$146.07M−$196.04M−134.2%
2024$145.24M−$76.42M−52.6%
2023$146.03M−$143.10M−98.0%
2022$157.07M−$165.29M−105.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$146.07M$140.12M−$90.71M−$196.04M−134.2%
2024$145.24M$139.23M−$119.44M−$76.42M−52.6%
2023$146.03M$141.09M−$129.54M−$143.10M−98.0%
2022$157.07M$151.86M−$142.20M−$165.29M−105.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KPTI Valuation vs Biotechnology Median

Median of 608 stocks
MetricKPTIBiotechnology medianvs median
P/S ratio0.0713.300.0x the median
Profit margin−153.28%−38.31%115.0 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Karyopharm Therapeutics Inc. (KPTI) at $9.63M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 228.

Over the past 52 weeks the price has ranged from $0.31 to $10.99. The most recent close on file for KPTI is $0.42, dated October 21, 2026. That is +$0.07 (+18.35%) against the previous close. The latest close sits 36.9% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $146.07M. That is +0.57% against the prior fiscal year, when revenue was $145.24M. The same year closed with a net loss of $196.04M. The reported profit margin is −153.28%. That is 115 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −14.33.

Across the 4 fiscal years on file, revenue moves from $157.07M in 2022 to $146.07M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 0.07 times revenue. On price-to-sales that is 0 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −93.40%. Across 10 years the annualized return works out at −43.54%. Beta against the wider market is reported at 1.04. Annualized volatility over the trailing 10 years is 91.18%.

Growth & Income

The record shows no dividend for KPTI.

The strongest complete calendar year on file is 2019 at +104.59%; the weakest is 2023 at −74.56%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the total return is −94.23%.

Peer Comparison

Karyopharm Therapeutics Inc. (KPTI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Karyopharm Therapeutics Inc. KPTI $9.63M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Karyopharm Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Visit website →